Introduction
============

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third cause of cancer-related mortality worldwide (Jemal et al. [@b15]). HCC is generally diagnosed at a late stage, and the majority of HCC patients die within 1 year after diagnosis. The only curative treatment options are resection and transplantation, but recurrence rates are high (Forner et al. [@b12]). HCC is highly resistant to conventional chemotherapy, and targeted therapy with the multi-kinase inhibitor sorafenib was a breakthrough in the treatment of unresectable, advanced HCC (Llovet et al. [@b23]). Sorafenib blocks tumor cell proliferation and angiogenesis mainly by targeting Raf kinases and vascular endothelial growth factor (VEGF)/platelet-derived growth factor (PDGF) receptor tyrosine kinases (Wilhelm et al. [@b43]; Liu et al. [@b22]). Based on the results of a large randomized phase III study, sorafenib is presently the standard systemic therapy for HCC patients with advanced disease, whereas other targeted therapies for treatment of HCC are under development (Worns and Galle [@b44]). However, the improved median survival of HCC patients treated with sorafenib is limited to 3 months (Llovet et al. [@b23]), and therefore combination therapies with sorafenib were encouraged in the future clinical trial design for HCC (Llovet et al. [@b24]). Aiming at prolonged survival, both preclinical (Chen et al. [@b9]; Zhang et al. [@b49]) and clinical studies (Abdel-Rahman and Fouad [@b1]) of sorafenib-based combination treatments have been performed.

There is accumulating evidence for the involvement of sphingosine 1-phosphate (S1P) and sphingosine kinase 1 (SK1) in cancer (Pyne and Pyne [@b32]). SK1 converts tumor suppressive sphingosine to S1P, which promotes proliferation, migration, angiogenesis and metastasis. The sphingosine analog FTY720 (Fingolimod, Gilenya™ Stein, Switzerland) is an immunosuppressant that has recently been approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of relapsing multiple sclerosis. In addition to its immunomodulatory effects, FTY720 acts as a competitive inhibitor to SK1 and targets the enzyme for degradation (Tonelli et al. [@b39]), thereby preventing the conversion of sphingosine to S1P. Sphingosine kinase 2 converts FTY720 to (S)-FTY720 phosphate, which inhibits the effects of S1P signaling by acting directly as a functional antagonist to the S1P1 receptor (Brinkmann et al. [@b8]). FTY720 also exerts additional S1P receptor-independent antitumor effects (Brinkmann et al. [@b7]; Pyne and Pyne [@b32]; Pitman et al. [@b31]). Combined treatment with sorafenib and a synthetic inhibitor to SK2 has earlier shown antitumor activity in HCC xenografts (Beljanski et al. [@b5]).

FTY720 has shown antitumor and antiangiogenic effects in animal models of breast cancer, prostate cancer, lung cancer and malignant melanoma (Azuma et al. [@b4]; Chua et al. [@b10]; Schmid et al. [@b35]; LaMontagne et al. [@b16]; Zhou et al. [@b51]; Pereira et al. [@b29]; Saddoughi et al. [@b34]). Moreover, FTY720 has been shown to selectively induce cytotoxicity in hepatoma cell lines, and to suppress tumor growth with no apparent side-effects in a mouse model of HCC (Lee et al. [@b17]). Whereas the cytostatic and antiangiogenic effects of sorafenib counteract tumor development, sorafenib has also been shown to promote tumor invasiveness and metastasis in a mouse model of HCC (Zhang et al. [@b48]). In contrast, treatment with FTY720 suppressed liver tumor metastasis after liver transplantation and resection in rat models of HCC (Ushitora et al. [@b40]; Li et al. [@b18]). FTY720 has also been shown to enhance the effects of chemotherapeutic treatment of cell lines and animal models representing breast cancer, lymphoma, neuroblastoma, and prostate cancer cells (Pchejetski et al. [@b28]; Alinari et al. [@b2]; Mousseau et al. [@b27]; Li et al. [@b19]; Marvaso et al. [@b26]). In view of these observations, we hypothesized that sorafenib and FTY720 could act synergistically to suppress survival and growth of HCC cells, and therefore investigated the cytotoxic effects of combined treatment of these two compounds on HCC cell lines.

Materials and Methods
=====================

Sorafenib tosylate (BAY 54-9085) was provided by Bayer HealthCare Pharmaceuticals (Montville, NJ), FTY720 (Fingolimod) was purchased from Cayman Chemical Ann Arbor, Michigan, USA. (MI). Stock solutions of 100 mmol/L sorafenib and of 20 mmol/L FTY720 dissolved in Dimethyl sulfoxide (DMSO) were aliquoted and deep-frozen. Primary antibodies against poly-ADP ribose polymerase (PARP) and light chain 3II (LC3II) were from Cell Signaling (Cell Signaling Technology Inc., Danvers, MA). p62 from Sigma-Aldrich LLC. (St. Louis, MO), Apoptosis-inducing factor (AIF) from Santa Cruz Biotechnology, Inc. (Texas, USA), cytochrome *c* oxidase (Cox IV) from Novus Biologicals, LLC, (Littleton, Colorado, USA), Cytochrome *c* (Cyt *c*) from BD Bioscience (San Jose, CA), *α*-Tubulin and *β*-Actin from Sigma-Aldrich Co. LLC. were used. Secondary fluorescent antibodies, goat anti-rabbit and goat anti-mouse, were purchased from LI-COR® (Nebraska, USA). Cell culture medium and supplements were purchased from Invitrogen (Eugene, OR).

Cell culture
------------

The human hepatocellular-carcinoma cell line Huh7 was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany) and HepG2 cell line was purchased from ATCC. Huh7 cells were cultured in Dulbecco\'s modified Eagle\'s Medium (DMEM) supplemented with 10% fetal bovine serum, penicillin 100 U/mL and streptomycin 100 *μ*g/mL at 37°C in an atmosphere containing 5% CO~2~, whereas HepG2 cells were cultured in DMEM supplemented with 10% fetal bovine serum at 37°C in an atmosphere containing 5% CO~2~.

Viability assay
---------------

Viability/cytotoxicity caused by sorafenib and FTY720 was determined using the cell proliferation kit II ((2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetra-zolium-5-Carboxanilide) XTT) from Roche Diagnostics (Basel, Switzerland) according to the manufacturer\'s instructions. The cells were seeded at a density of 10 × 10^3^, 6 × 10^3^ or 5 × 10^3^ cells per well for Huh7 cell line and 15 × 10^3^, 10 × 10^3^ or 8 × 10^3^ cells per well for HepG2 cell line in 96-well plates depending on the treatment time and allowed to adhere overnight. Subsequently the cells were treated for 24, 48 and 72 h with different doses of sorafenib alone or in combination with FTY720 or vehicle (0.04% DMSO). In the final step they were incubated with the XTT solution for two hours. The optical density reflecting viable cells was obtained by measuring the absorbance at 470 nm and subtracting the background absorbance at 750 nm. Dose--response curves were constructed for treatment with FTY720. The least cytotoxic dose, which had a marginal effect on the viability of cells when used as a single agent, was determined from two individual experiments by comparing the top and bottom plateaus of the dose--response curve. In order to study sensitization of HCC cells to treatment with sorafenib, this dose was used in the subsequent experiments.

Cell death analysis by flow cytrometry
--------------------------------------

The Annexin-V-FLUOS Staining Kit, ROCHE Diagnostics GmbH (Mannheim, Germany) was used to distinguish between viable and dead cells following treatment with sorafenib in the presence or absence of FTY720. Huh7 cells were seeded at a density of 8.0 × 10^5^ in 25 cm^2^ flasks and allowed to adhere overnight. Thereafter, the cells were treated for 6, 12, or 24 h with different doses of sorafenib/sorafenib and FTY720 or DMSO as indicated in the Results section. Cells were harvested and labeled with annexin-V and propidium iodide (PI) according to the manufacturer\'s instruction and analyzed by flow cytometry in BD FACS caliber (BD Bioscience).

Cell cycle analysis by flow cytrometry
--------------------------------------

The BD Cycletest Plus reagent kit, BD Biosciences was used to determine the cell cycle distribution and sub G1 fractions. Huh7 cells were seeded at the densities of 4.0 × 10^5^, 4.8 × 10^5^ or 8.0 × 10^5^ cells in 25 cm^2^ flasks depending on the treatment time and allowed to adhere overnight. Subsequently the cells were treated for 24 and 48 h with different doses of sorafenib alone or in combination with FTY720 or vehicle (0.04% DMSO). The cells were harvested and stained with PI according to the manufacturer\'s instruction. Cell cycle distribution was analyzed using BD LSRIl (BD Bioscience) and the data were analyzed using the ModFit LT v3.3, (BD Bioscence).

Western blot analysis
---------------------

Whole cell protein was extracted from the Huh7 cells, using NP-40 lysis buffer (Invitrogen) containing 50 mmol/L Tris, 250 mmol/L NaCl, 5 mmol/L Ethylenediaminetetraacetic acid (EDTA), 50 mmol/L NaF, 1 mmol/L Na~3~VO~4~, 1% NP-40 and 0.02% NaN~3~, to which protease inhibitor cocktail p8340 had been added. Protein concentration was measured using Biorad DC protein concentration determination (Bio-Rad Laboratories Inc., Berkeley, California, USA) and 100 *μ*g of total protein was separated with Nu-PAGE (Invitrogen) using gels of different concentrations depending on the size of the protein of interest. Proteins were transferred to either PVDF (Immobilon®-P; Millipore, Billerica, MA) or to nitrocellulose membranes (Thermo Scientific, Waltham, Massachusetts, USA) at 33 mAmp for 1 h using a semidry blotter HoeferTM TE 70 (Amersham Biosciences Corp. New Jersey, USA). The membranes were blocked in 5% non-fat milk solution in Phosphate-buffered saline (PBS)-T (0, 1% Tween 20) at room temperature for 1 h before incubation with individual primary antibodies at 4°C over-night. The membranes were washed for 6 × 5 min with PBS-T followed by 1 h incubation with HRP/Fluorescence-conjugated secondary antibodies at room temperature. HRP-conjugated antibodies were detected using Supersignal west Femto Maximum Sensitivity Substrate (Thermo Scientific) whereas Fluorescence conjugated antibodies were imaged directly using LICOR imaging system (LI-COR Biosciences, Ltd., Nebraska, USA). Relative density from western blots was calculated using ImageJ 1.48v software, background was subtracted from individual bands.

Confocal microscopy
-------------------

Huh7 cells were grown on sterile coverslips in six-well plates at the density of 3.0 × 10^5^ cells overnight. Cells were then treated by different doses of sorafenib in the presence or absence of FTY720 for 24 h. Thereafter, the cells were fixed with ice-cold methanol, permeabilized with 3:1 ethanol: acetic acid solution. Cells were blocked with 5% BSA in PBS for 1 h at room temperature. Preparations were mounted on slides using mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc. Burlingame, CA) and examined with a confocal microscope (Nikon Confocal Microscope; Nikon Corporation, Tokyo, Japan).

Cytosolic and mitochondrial fraction
------------------------------------

Harvested Huh7 cells (2 × 10^6^) were washed in ice-cold PBS and incubated for 25 min on ice with 300 *μ*L of ice cold buffer A (250 mmol/L Sucrose, 20 mmol/L (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HEPES-KOH (pH 7.4), 10 mmol/L KCl, 1 mmol/L Na-EGTA, 1 mmol/L Na-EDTA, 1.5 mmol/L MgCl~2~, 1 mmol/L dithiothreitol (DTT), 0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF), and cocktail of protease inhibitors \[Sigma-Aldrich Co. LLC.\]). Cells were then lysed with 30 strokes using a syringe fitted with a needle (22 gauges and 30 mm) and centrifuged at 4°C (600 g). The supernatant was centrifuged at 21,000*g* for 10 min. The supernatant (cytosol) was saved at −20°C and the pellet (mitochondria) was incubated for 20 min on ice in 100 *μ*L of buffer B (50 mmol/L HEPES (pH 7.4), 1% Nonidet P-40 (NP-40), 10% (v/v) glycerol, 1 mmol/L Na-EDTA, 2 mmol/L DTT, 0.1 mmol/L PMSF, and cocktail of protease inhibitors \[Sigma-Aldrich Co. LLC.\]). Samples were centrifuged at 21,000*g* for 15 min, the supernatant containing mitochondrial proteins was stored at −20°C. 40 *μ*g protein of each fraction were electrophoresed in 4--10% precasted SDS-PAGE gel (Thermo Scientific) prior to immunoblotting (see previous section).

Statistical analyses
--------------------

Paired *T*-test was performed to assess the difference in viability between cells treated with sorafenib alone and with sorafenib and 8 *μ*mol/L or 2 *μ*mol/L of FTY720. Differences in cell death and cell cycle distribution between groups were analyzed by analysis of variance, with the least significance difference (LSD) as *post hoc*. \**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005.

Results
=======

Increased cytotoxicity after combined treatment with sorafenib and FTY720
-------------------------------------------------------------------------

FTY720 has earlier shown cytotoxicity toward HCC cells (Lee et al. [@b17]; Ushitora et al. [@b40]; Li et al. [@b18]). In order to investigate whether FTY720 could sensitize HCC cells to treatment with sorafenib, we initially titrated the dose of FTY720 using the XTT assay as an estimation of viability. The least cytotoxic dose for FTY720 was determined to 8 and 2 *μ*mol/L for Huh7 and HepG2, respectively (see Materials and Methods). The decreased viability induced by treatment of HCC cells with increasing doses of sorafenib for 24, 48 or 72 h was significantly enhanced after cotreatment of Huh7 and HepG2 with 8 *μ*mol/L or 2 *μ*mol/L of FTY720 respectively, Figure[1](#fig01){ref-type="fig"}. The effect increased over time and was more pronounced in Huh7 as compared to HepG2. These results indicate that FTY720 sensitizes HCC cells to cytotoxicity induced by sorafenib.

![Cell viability following combined treatment with sorafenib and FTY720. Huh7 and HepG2 cells were treated with increasing doses of sorafenib in the presence or absence of 8 or 2 *μ*mol/L of FTY720, respectively for 24, 48 or 72 h, where after XTT assay was performed. The graphs are based on at least four individual experiments. The boxes represent the interquartile range (IQR) for each treatment, the bands represent the median, while the whiskers represent the highest and lowest values, respectively, that are not considered outliers. Outliers that are 1.5× the IQR or more are presented as circles. The paired *T*-test was performed to assess the difference in viability between cells treated with sorafenib alone and with sorafenib and 8 or 2 *μ*mol/L of FTY720. \**P* \< 0.05, \*\**P* \< 0.005.](prp20003-e00171-f1){#fig01}

Effects on cell cycle distribution following combined treatment with sorafenib and FTY720
-----------------------------------------------------------------------------------------

In order to examine the mechanisms behind the enhanced cytotoxicity following combined treatment, further studies were performed in the Huh7 cell line, which, similarly to a majority of primary HCC, and in contrast to HepG2, harbor mutated p53 (Bressac et al. [@b6]). To investigate whether the cell cycle distribution was affected by the combined treatment, Huh7 cells were treated with sorafenib in the presence or absence of FTY720 for 24 or 48 h. After both 24 and 48 h, combined treatment with 2 *μ*mol/L of sorafenib and 8 *μ*mol/L of FTY720 caused a significant accumulation of cells in the G1 phase and a concomitant decrease of the number of cells in the S phase compared to treatment with sorafenib alone, Figure[2](#fig02){ref-type="fig"}. In contrast, at higher doses of sorafenib, cotreatment with 8 *μ*mol/L of FTY720 caused a significant decrease or increase of cells in the G2 phase after 24 or 48 h, respectively. At the latter time point, FTY720 also significantly increased the sub G1 fraction, representing dead cells, observed after treatment with 6 *μ*mol/L or 10 *μ*mol/L doses of sorafenib alone, Figure[2](#fig02){ref-type="fig"}.

![Cell cycle distribution following combined treatment with sorafenib and FTY720. Huh7 cells were treated with sorafenib in the absence or presence of 8 *μ*mol/L FTY720 and stained with propidium iodide prior to analysis by flow cytometry for (A) 24 h or (B) 48 h. Cytograms show one representative experiment out of two (upper part). The columns in the histograms (lower part) show mean of two individual experiments, error bars represent standard deviation. Differences between groups were analyzed by analysis of variance, with the least significance difference as *post hoc*. \**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005.](prp20003-e00171-f2){#fig02}

Together, the cell cycle analysis shows synergistic effects of combined treatment with FTY720 and sorafenib on both cell cycle progression and cell death.

Induction of apoptosis after combined treatment with sorafenib and FTY720
-------------------------------------------------------------------------

To further investigate the mechanisms behind the cytotoxic effect of combined treatment with sorafenib and FTY720, early signs of apoptosis were assessed by flow cytometry analysis of cells labeled with Annexin-V-Fluos and PI. A significant increase in presumably apoptotic, secondary necrotic and necrotic cells in the lower right, upper right and upper left quadrants, respectively, was observed after combined treatment with 10 *μ*mol/L of sorafenib and 8 *μ*mol/L of FTY720 as compared to treatment with sorafenib alone for 6 hours, Figure[3](#fig03){ref-type="fig"}. Condensation of nuclei was observed after treatment with 10 and 20 *μ*mol/L of sorafenib for 24 h, and was further enhanced after cotreatment with 8 *μ*mol/L of FTY, Figure[4](#fig04){ref-type="fig"}A. In order to investigate different apoptotic pathways, cleaved PARP and cytosolic AIF, markers for caspase-dependent and -independent apoptosis, respectively, were analyzed by western blotting. Treatment with a high dose of sorafenib (20 *μ*mol/L) for 24 h caused cleavage of PARP in the absence of FTY720, whereas lower doses did not, Figure[4](#fig04){ref-type="fig"}B. The ratio of cleaved PARP increased when the cells were treated with 20 *μ*mol/L of sorafenib together with 8 *μ*mol/L of FTY720. Furthermore, a weak band representing cleaved PARP was observed when 10 *μ*mol/L of sorafenib was combined with 8 *μ*mol/L of FTY720. Treatment with either 2 or 10 *μ*mol/L of sorafenib or 8 *μ*mol/L of FTY720 alone for 24 h induced a slight release of AIF into the cytosol, which was further increased after combination treatment, Figure[4](#fig04){ref-type="fig"}C. The purity of the mitochondrial and cytosolic fractions was confirmed using the mitochondrial and cytoskeletal markers COX IV and *β*-actin, respectively. The expression of COX IV, declined after treatment with 10 *μ*mol/L sorafenib ±8 *μ*mol/L FTY720. The role of mitochondria-mediated apoptosis was supported by release of Cyt *c* into the cytosol. Taken together, these results indicate that the induction of cell death by combined treatment with sorafenib and FTY720 could partly be attributed to mitochondria-mediated apoptosis in both caspase-independent and, at higher doses of sorafenib, caspase-dependent manners.

![Induction of cell death following treatment with sorafenib and FTY720. Huh7 cells were exposed to 10 *μ*mol/L of sorafenib and/or 8 *μ*mol/L of FTY720 for 6 h and stained with FITC-Annexin V and propidium iodide (PI) prior to analysis by flow cytometry. (A) Cytograms show one representative experiment out of two, the percentages show unaffected cells which are negative for both stains (lower left quadrant), early apoptotic cells stained with Annexin V (lower right quadrant), late apoptotic cells stained with both Annexin V and PI (upper right quadrant) and necrotic cells stained with only PI (upper left quadrant). (B) Histogram showing total percentage of apoptotic and necrotic cells which were stained with Annexin V, PI or both, mean of two individual experiments. Error bars represent standard deviation. Differences between groups were analyzed by analysis of variance, with the least significance difference as *post hoc*. \**P* \< 0.05.](prp20003-e00171-f3){#fig03}

![Apoptosis following combined treatment with sorafenib and FTY720. (A) Huh7 cells were treated with increasing doses of sorafenib in the presence or absence of 8 *μ*mol/L FTY720 for 24 h, fixed with ice-cold methanol and stained with 4′,6-diamidino-2-phenylindole (DAPI) prior to visualization of nuclei (in blue) by confocal microscopy. (B) Western blot showing poly-ADP ribose polymerase (PARP) cleavage as an indicator of caspase-mediated apoptosis following treatment with 10 or 20 *μ*mol/L of sorafenib in the presence or absence of 8 *μ*mol/L FTY720. Tubulin was used as a loading control. In the histogram relative density was used to calculate the percentage of cleaved PARP compared to total PARP. (C) Western blots showing translocation of apoptosis-inducing factor (AIF) from mitochondria into the cytosol as an indicator of caspase-independent apoptosis. Huh7 cells were treated with 2 or 10 *μ*mol/L of sorafenib in the presence or absence of 8 *μ*mol/L FTY720 for 24 h, fractionated into mitochondrial and cytosolic compartments and analyzed for the protein levels of AIF and cytochrome *c*. In the histogram, relative density was used to calculate the percentages of cytosolic and mitochondrial fractions for both proteins. *β*-actin was used as cytoskeletal and COX IV as mitochondrial control. In all cases, one of two individual experiments is shown.](prp20003-e00171-f4){#fig04}

Effect of combined treatment with sorafenib and FTY720 on proteins involved in autophagy
----------------------------------------------------------------------------------------

The earlier observed opposing effects of sorafenib and FTY720 on autophagy directed us to investigate hallmarks of this cellular process following combined treatment of Huh7 cells with sorafenib and FTY720. Treatment with high doses of sorafenib alone caused increased levels of LC3II protein concurrently with decreased p62 protein levels, Figure[5](#fig05){ref-type="fig"}. In contrast, an increase in both LC3II and p62 protein levels was observed following treatment with FTY720 alone. Cotreatment with FTY720 further increased the induction of LC3II protein observed after treatment with sorafenib alone, and attenuated the sorafenib-induced decrease in p62 protein levels. These results indicate that sorafenib may induce autophagosome formation, whereas FTY720 may inhibit the fusion of autophagosomes with lysosomes.

![Western blots showing the levels of autophagic proteins following cotreatment with sorafenib and FTY720. Huh7 cells were treated with increasing doses of sorafenib with or without 8 *μ*mol/L FTY720 for 24 h. Protein levels of (A) LC3-ll and (B) p62 are shown in the blot and in the histograms. Relative densities from two different experiments are presented in the histograms. Values are normalized against vehicle control as well as *β*-actin. Error bars represent standard deviation.](prp20003-e00171-f5){#fig05}

Discussion
==========

At present, sorafenib is the standard systemic therapy for treatment of patients with advanced HCC. Combination of sorafenib with compounds that target alternate mechanisms of action may lead to new therapeutic options resulting in decreased risk for metastasis and increased survival. Among the combination therapies undergoing clinical trials (Villanueva and Llovet [@b41]), analogs of bioactive sphingolipids are currently not being tested in combination with sorafenib, despite their suggested potential as anticancer agents (Pyne et al. [@b33]; Delgado et al. [@b11]). In this study, we have investigated the effects of combined treatment of HCC cells with sorafenib and the sphingosine analog FTY720, which is approved for treatment of relapsing multiple sclerosis. We have presently shown that the sphingosine analog FTY720 sensitized HCC cells to treatment with sorafenib. At doses of FTY720 that itself showed no cytotoxicity, cotreatment with sorafenib significantly increased the effects on viability, cell cycle progression and cell death observed after treatment with sorafenib alone. Furthermore, whereas sorafenib alone has been shown to favor cancer cell survival by inducing autophagy (Shi et al. [@b36]; Shimizu et al. [@b37]), the autophagic process appeared to be blocked by cotreatment with FTY720.

Both FTY720 and sorafenib have earlier been shown to induce arrest in the G1 phase of the cell cycle in human cancer cells of various origins including HCC (Permpongkosol et al. [@b30]; Lee et al. [@b17]; Huether et al. [@b13]; Zheng et al. [@b50]; Marvaso et al. [@b26]). The relatively low dose of FTY720 used in this study had little effect on the cell cycle progression. However, it sensitized the Huh7 cells to treatment with sorafenib, as combined treatment with FTY720 and sorafenib caused significant accumulation of cells in the G1 phase at a dose of sorafenib that alone had no effect. At higher doses of sorafenib, combined treatment also caused a significant increase in the sub G1 fraction, indicating cell death. Earlier studies have shown induction of both apoptosis and necrosis in response to FTY720 treatment (Zhang et al. [@b47]; Pitman et al. [@b31]). We observed a significant synergistic increase in the fraction of apoptotic and necrotic cells after combined treatment with sorafenib and FTY720 for six hours. Similarly to earlier observations (Hung et al. [@b14]), no PARP-cleavage was observed following treatment with 8 *μ*mol/L of FTY720 for 24 h. However, the ratio of cleaved PARP resulting from treatment with sorafenib was increased by cotreatment with FTY720. The relatively high doses of sorafenib required for PARP cleavage are in accordance with earlier observations of sorafenib-induced apoptosis (Yu et al. [@b45]). This result raised the possibility that caspase-independent apoptosis may have contributed to the cell death observed by detection of Annexin-V and PI. Our results support a modest induction of caspase-independent apoptosis, as a partial release of AIF into the cytosol was observed, whereas a fraction of AIF remained in the mitochondria after treatment of Huh7 cells with sorafenib and FTY720. The observed release of AIF into the cytosol might have triggered the extramitochondrial release of cyt c as demonstrated earlier (Loeffler et al. [@b25]; Liu et al. [@b21]).

Treatment with sorafenib has been shown to induce autophagy in HCC cells (Tai et al. [@b38]), and involvement of autophagy in acquired resistance to sorafenib in HCC cell lines has been demonstrated (Zhai et al. [@b46]). As autophagy counteracts the anti-proliferative effects of sorafenib, we investigated the effects of combined treatment with sorafenib and FTY720. Different studies have reported either induction (Zhang et al. [@b47]; Wallington-Beddoe et al. [@b42]; Liao et al. [@b20]) or blockage of autophagy by treatment of cancer cells with FTY720, the latter leading to enhanced effect of milatuzumab in mantle cell lymphoma (Alinari et al. [@b3]). During cytoprotective autophagy, the p62 protein levels decrease due to degradation in the autolysosome, whereas increased p62 levels may reflect a blockage in autophagy. Our results indicate that treatment with sorafenib alone induced autophagy in Huh7, as increasing doses of sorafenib caused a gradual slight increase in LC3II protein and concomitant decrease in p62 protein levels. In contrast, we observed higher protein levels of both LC3II and p62 following combined treatment with sorafenib and FTY720, indicating that FTY720 protects both proteins from degradation, possibly through blocking the conversion of autophagosomes to autolysosomes. Inhibition of autophagy with chloroquine has earlier been shown to potentiate sorafenib-induced apoptosis in vitro and antitumor effects in vivo in HCC cell lines and Huh7 xenografts, respectively (Shi et al. [@b36]; Shimizu et al. [@b37]). In line with these observations, inhibition of autophagy by FTY720 may underlie our observed synergistic effects on cell cycle arrest and cell death in response to combined treatment with sorafenib and FTY720.

In conclusion, we have shown that FTY720 enhanced the decrease in viability observed after treatment of Huh7 and HepG2 cells with sorafenib alone. Combined treatment of Huh7 cells with sorafenib and FTY720 generated synergistic effects on cell cycle arrest and apoptosis, possibly through blockage of autophagy. Our results suggest that FTY720 sensitizes HCC cells to sorafenib, and enhances its cytotoxic effects. This encourages further studies aiming at combinatorial use of FTY720 and sorafenib, both of which are in clinical use, in order to improve the outcome of HCC treatment.
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